section name header

Y-Site Injection Compatibility (1:1 Mixture)

Blinatumomab

(Mfr: AMG)(Conc: 0.125 mcg/mLb)

I

Meropenem

(Mfr: ARR)(Conc: 8.3 mg/mLb)

Remarks:

Persistent particulate formation

Ref:

3405,3417